CA2292629A1 - Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione - Google Patents

Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione Download PDF

Info

Publication number
CA2292629A1
CA2292629A1 CA002292629A CA2292629A CA2292629A1 CA 2292629 A1 CA2292629 A1 CA 2292629A1 CA 002292629 A CA002292629 A CA 002292629A CA 2292629 A CA2292629 A CA 2292629A CA 2292629 A1 CA2292629 A1 CA 2292629A1
Authority
CA
Canada
Prior art keywords
composition
thiazolidine
dione
pyridyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002292629A
Other languages
French (fr)
Other versions
CA2292629C (en
Inventor
Paul Nigel Wray
Hamish Ross
Jeffrey Roger Granett
Jaikrishna Patel
Robin Kevin John Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
Paul Nigel Wray
Hamish Ross
Smithkline Beecham Corporation
Jeffrey Roger Granett
Jaikrishna Patel
Robin Kevin John Price
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Paul Nigel Wray, Hamish Ross, Smithkline Beecham Corporation, Jeffrey Roger Granett, Jaikrishna Patel, Robin Kevin John Price, Smithkline Beecham P.L.C. filed Critical Paul Nigel Wray
Publication of CA2292629A1 publication Critical patent/CA2292629A1/en
Application granted granted Critical
Publication of CA2292629C publication Critical patent/CA2292629C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.
CA002292629A 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Expired - Fee Related CA2292629C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9711683.4 1997-06-05
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GB9712851.6 1997-06-18
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002333352A Division CA2333352A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
CA2292629A1 true CA2292629A1 (en) 1998-12-10
CA2292629C CA2292629C (en) 2004-01-06

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002333352A Abandoned CA2333352A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione
CA002292629A Expired - Fee Related CA2292629C (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002333352A Abandoned CA2333352A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione

Country Status (29)

Country Link
EP (1) EP0998284A1 (en)
JP (1) JP2001521553A (en)
KR (1) KR20010013410A (en)
CN (3) CN1526391A (en)
AP (1) AP1214A (en)
AR (2) AR015120A1 (en)
AU (1) AU8215098A (en)
BG (1) BG104048A (en)
BR (1) BR9810405A (en)
CA (2) CA2333352A1 (en)
CO (1) CO4940400A1 (en)
DZ (1) DZ2510A1 (en)
EA (1) EA002384B1 (en)
GB (1) GB9711683D0 (en)
HU (1) HUP0004070A3 (en)
ID (1) ID24264A (en)
IL (1) IL133074A0 (en)
MX (1) MXPA99011322A (en)
NO (2) NO995938L (en)
NZ (2) NZ523725A (en)
OA (1) OA11306A (en)
PE (1) PE78899A1 (en)
PL (1) PL337201A1 (en)
SK (1) SK164899A3 (en)
TR (2) TR200002790T2 (en)
TW (1) TW570797B (en)
UY (1) UY25032A1 (en)
WO (1) WO1998055122A1 (en)
ZA (2) ZA9811572B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
BR0009934A (en) 1999-04-23 2002-06-04 Smithkline Beecham Plc Pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (en) * 1987-09-04 1999-12-15 Beecham Group Plc SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
BG104048A (en) 2000-07-31
NO995938L (en) 2000-02-02
NO995938D0 (en) 1999-12-03
NZ523725A (en) 2004-09-24
OA11306A (en) 2003-10-22
SK164899A3 (en) 2000-11-07
CN1430959A (en) 2003-07-23
HUP0004070A3 (en) 2002-03-28
EA199901116A1 (en) 2000-06-26
EA002384B1 (en) 2002-04-25
WO1998055122A1 (en) 1998-12-10
CN1259050A (en) 2000-07-05
NZ513922A (en) 2001-09-28
ID24264A (en) 2000-07-13
BR9810405A (en) 2000-08-29
CA2333352A1 (en) 1998-12-10
HUP0004070A2 (en) 2002-02-28
AU8215098A (en) 1998-12-21
PL337201A1 (en) 2000-08-14
CN1526391A (en) 2004-09-08
DZ2510A1 (en) 2003-01-25
AR015120A1 (en) 2001-04-18
IL133074A0 (en) 2001-03-19
UY25032A1 (en) 1998-11-26
TR199902963T2 (en) 2000-02-21
AP1214A (en) 2003-10-08
KR20010013410A (en) 2001-02-26
GB9711683D0 (en) 1997-08-06
ZA984826B (en) 1999-08-03
AP9901696A0 (en) 1999-12-31
PE78899A1 (en) 1999-10-22
JP2001521553A (en) 2001-11-06
EP0998284A1 (en) 2000-05-10
NO20040738L (en) 2000-02-02
ZA9811572B (en) 1999-07-22
TR200002790T2 (en) 2001-11-21
MXPA99011322A (en) 2004-12-02
CA2292629C (en) 2004-01-06
TW570797B (en) 2004-01-11
CO4940400A1 (en) 2000-07-24
CN1112926C (en) 2003-07-02
AR008198A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
WO2001035941A3 (en) Novel composition based on a thiazolidinedione and metformin and use
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
CA2203033A1 (en) Compounds and compositions for delivering active agents
CA2292629A1 (en) Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione
CA2380087A1 (en) Beta-carboline drug products
HUP0203060A3 (en) Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same
AU6611396A (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
CA2041417A1 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2175971A1 (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
CA2046069A1 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
HUP9802143A3 (en) Heterocyclic compounds of 5 members in the ring, process for producing them and pharmaceutical compositions containing them
CA2238389A1 (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
CA2220019A1 (en) Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2042934A1 (en) Treatment of ocular hypertension with an ocular synergistic combination
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.
HUP9900320A3 (en) Optically active thiazolidinone derivatives, preparation thereof, pharmageutical compositions containing these compounds as active ingredients and use of thia-or oxazolidine derivatives for preparation of pharmaceutical compositions
BG106151A (en) Pharmaceutical complex
CA2041240A1 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
CA2352430A1 (en) New pharmaceutical composition and the process for its preparation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed